| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/25/2009 | CN100471835C Anti-hypercholesterolemic compounds |
| 03/25/2009 | CN100471509C Medicine for treating tympanitis and otitis externa, and preparing method |
| 03/25/2009 | CN100471508C Medicine for treating cardiac and cerebral vascular diseases and its prepn process |
| 03/25/2009 | CN100471500C Medicinal composition contg. glucoside of pueravia flower and its application |
| 03/25/2009 | CN100471498C Pharmaceutical composition of ligustrazine and carthamin yellow |
| 03/25/2009 | CN100471494C Butylphthalide dripping pill and preparing method |
| 03/25/2009 | CN100471492C Use of hydroxyoleic acid and similar compounds in the production of medicaments |
| 03/24/2009 | US7507816 Compounds for treatment of inflammation, antidepressants, nervous system disorders, cardiovascular disorders or analgesics from mannich reaction |
| 03/24/2009 | US7507807 Expression vector comprising nucleotide sequences coding tumor necrosis factor receptor protein (TWEAK) for use in identifying modulators for treatment of inflammatory, cardiovacullar, vision and cancer disorders |
| 03/24/2009 | US7507767 Sulfonamide-containing benzene derivatives which exhibit anti-inflammatory and immunodulatory activity |
| 03/24/2009 | US7507730 Substituted pyrazolo[1,5-a]pyrimidines as potassium channel activators |
| 03/24/2009 | US7507720 5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 03/24/2009 | US7507717 Inhibitors of neuronal amine transporters of neurotransmitters, such as noradrenaline, serotonin, dopamine, glutamic acid and glycine; pain, inflammation, incontinence, cardiovascular conditions and mood disorders |
| 03/24/2009 | US7507712 NOV protein: an anti-angiogenic agent and its use, in particular for the treatment of cancer |
| 03/24/2009 | US7507705 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 03/24/2009 | US7507572 Compositions comprising lactobacillus plantarum strains in combination with tannin and new lactobacillus plantarum strains |
| 03/24/2009 | US7507414 Therapeutic polypeptide with prolonged shelf-life and increased half life for use in treatment of cell proliferative, cardiovascular, inflammatory and autoimmune disorders |
| 03/24/2009 | US7507412 for drug screening; kits for collagen and/or platelet-collagen interaction; for treatment of thrombotic and cardiovascular events and disorders |
| 03/24/2009 | CA2450690C Improved chelator conjugates |
| 03/24/2009 | CA2431100C Dihydroindole and tetrahydroquinoline derivatives |
| 03/24/2009 | CA2422380C Pyrazole compounds useful as protein kinase inhibitors |
| 03/24/2009 | CA2421738C Purine ribosides as antiarrhythmics |
| 03/24/2009 | CA2382404C Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 03/24/2009 | CA2377904C Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances |
| 03/24/2009 | CA2352211C Sustained release matrix systems for highly soluble drugs |
| 03/24/2009 | CA2318479C G protein-related kinase mutants in essential hypertension |
| 03/19/2009 | WO2009036149A2 Methods for treatment of degenerative disease associated with apoptosis |
| 03/19/2009 | WO2009036108A1 Methods and compositions for inhibiting vascular leakage |
| 03/19/2009 | WO2009036064A1 Vegetable protein concentrate having a reduced insoluble dietary fiber content and an increased amount of soluble dietary fiber content |
| 03/19/2009 | WO2009035949A2 Soluble epoxide hydrolase inhibitors |
| 03/19/2009 | WO2009035927A2 Bis-cyclyl substituted ureas or amides as soluble epoxide hydrolase inhibitors |
| 03/19/2009 | WO2009035565A1 Prostaglandin analogues for implant devices and methods |
| 03/19/2009 | WO2009035543A1 Dual-acting antihypertensive agents |
| 03/19/2009 | WO2009035417A1 Neuroprotective agents |
| 03/19/2009 | WO2009035169A1 Peptide having anti-hypertensive activity |
| 03/19/2009 | WO2009035068A1 Novel 1,3,3-trimethyl-7-phenyl-3,4-dihydro-1h-quinoxalin- 2-one derivatives |
| 03/19/2009 | WO2009035067A1 Glucocorticoid receptor agonists consisting of 1,3,3-tri- methyl-7-phenyl-3,4-dihydro-1h-quinoxalin-2-one derivatives |
| 03/19/2009 | WO2009035055A1 Insulin-like growth factor-1 (igf-1) production promoter |
| 03/19/2009 | WO2009034541A2 Controlled release pharmaceutical dosage forms of trimetazidine |
| 03/19/2009 | WO2009034470A2 Future cardiac event biomarkers |
| 03/19/2009 | WO2009034111A1 Treatment of vasomotor symptoms |
| 03/19/2009 | WO2009033824A1 Use of a combination of beta-casokinin and cnp-22 as a therapeutic agent |
| 03/19/2009 | WO2009033823A1 Use of a peptide combination comprising urotensin ii as a therapeutic agent |
| 03/19/2009 | WO2009033822A2 Use of a combination of a cathepsin g fragment and teprotide as a therapeutic agent |
| 03/19/2009 | WO2009033821A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033820A2 Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis |
| 03/19/2009 | WO2009033819A2 Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids |
| 03/19/2009 | WO2009033818A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033817A2 Use of the combination of the hcv-1 e2 protein (484-499) and the human pancreatic polypeptide as a therapeutic agent |
| 03/19/2009 | WO2009033816A2 Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent |
| 03/19/2009 | WO2009033815A2 Use of the peptide combination ala-pro-gly-pro-arg with cecropin a as a therapeutic agent |
| 03/19/2009 | WO2009033814A2 Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent |
| 03/19/2009 | WO2009033813A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033812A2 Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent |
| 03/19/2009 | WO2009033811A2 Therapeutic uses of muroctasin and kisspeptin13 and compositions thereof |
| 03/19/2009 | WO2009033810A2 Use of antioxidant peptide a (phckrm) and aplha-casein (90-96) as therapeutic agents in eg the treatment of hiv infection |
| 03/19/2009 | WO2009033809A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033808A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033807A2 Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43 |
| 03/19/2009 | WO2009033806A2 Use of gly-pro-glu-oh (gpe) as a therapeutic agent |
| 03/19/2009 | WO2009033805A2 Use of somatostatin-14 as a therapeutic agent |
| 03/19/2009 | WO2009033804A2 Use of gamma- endorphin as a therapeutic agent |
| 03/19/2009 | WO2009033803A2 Use of the pentapeptide drlds and gamma-endorphin as therapeutic agents |
| 03/19/2009 | WO2009033802A2 Antide as a therapeutic agent |
| 03/19/2009 | WO2009033801A2 Syndyphalin alone or in combination with antide as a therapeutic agent |
| 03/19/2009 | WO2009033800A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033799A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033798A1 Combination of motilin and minigastrin as a therapeutic agent |
| 03/19/2009 | WO2009033797A2 Use of apelin-17 and peptide yy as therapeutic agents, eg for treating hbv infection |
| 03/19/2009 | WO2009033796A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033795A2 Use of a obestatin as a therapeutic agent |
| 03/19/2009 | WO2009033794A2 Use of endothelin-1, optionally in combination with obestatin, as a therapeutic agent |
| 03/19/2009 | WO2009033793A2 Pentagastrin as a therapeutic agent |
| 03/19/2009 | WO2009033792A2 Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent |
| 03/19/2009 | WO2009033791A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033790A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033789A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033788A2 Use of a jck-301, optionally in combination with big endothelin, as a therapeutic agent. |
| 03/19/2009 | WO2009033787A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033786A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033785A2 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hiv infection |
| 03/19/2009 | WO2009033784A2 Use of apelin-13 (qrprlshkgpmpf) and optionally aplha-casein (90-96) as a therapeutic agents in eg the treatment of hiv infection |
| 03/19/2009 | WO2009033783A2 Use of carbetocin to treat of eg aids or idiopathic pulmonary fibrosis |
| 03/19/2009 | WO2009033782A2 Use of a teprotide and optionally carbetocin to treat eg aids or idiopathic pulmonay fibrosis |
| 03/19/2009 | WO2009033781A2 Use of k237 as therapeutic agent |
| 03/19/2009 | WO2009033780A2 Use of growth hormone-releasing factor and/or k237 as a therapeutic agents |
| 03/19/2009 | WO2009033778A2 Mage-3 antigen and others for use as a therapeutic agent |
| 03/19/2009 | WO2009033777A1 Leuprolide analog as a therapeutic agent |
| 03/19/2009 | WO2009033776A1 Use of a defensin peptide as a therapeutic agent |
| 03/19/2009 | WO2009033775A2 Peptide alpmhir alone or in combination with peptide yvpfppf as therapeutic agent |
| 03/19/2009 | WO2009033774A2 Use of a laminin nonapeptide as a therapeutic agent |
| 03/19/2009 | WO2009033773A2 Use endothelin 2, alone or combined with a nonapeptide, a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033772A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033771A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033770A2 Calcitonin c-terminal flanking peptide for use as a therapeutic agent |
| 03/19/2009 | WO2009033769A2 Use of cortistatin 14 and others as a therapeutic agent |
| 03/19/2009 | WO2009033768A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033767A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033766A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033765A2 Use of a peptide as a therapeutic agent |